Mirum Pharmaceuticals, Inc. splits its revenue into 3 lines in its filings. The largest line in fiscal 2025, which ended Dec 31, 2025 was Livmarli at $360.0 million, 69% of the total.
USD in millions. The percent under a figure is the change from the year before.
| Line |
FY 2026
Sep 30, 2026
|
FY 2025
Dec 31, 2025
|
FY 2024
Dec 31, 2024
|
FY 2023
Dec 31, 2023
|
FY 2022
Dec 31, 2022
|
FY 2021
Dec 31, 2021
|
FY 2020
Dec 31, 2020
|
FY 2019
Dec 31, 2019
|
|---|---|---|---|---|---|---|---|---|
| Revenue |
671
|
521
|
337
|
186
|
77
|
19
|
—
|
—
|
| Livmarli |
482
+51.8%
share 71.9%
|
360
+68.8%
share 69.1%
|
213
+50.4%
share 63.3%
|
142
+88.9%
share 76.1%
|
75
+2292.0%
share 97.4%
|
3
share 16.4%
|
—
|
—
|
| Bile Acid Medicines |
188
+22.3%
share 28.1%
|
161
+31.0%
share 30.9%
|
123
+232.0%
share 36.5%
|
37
share 19.9%
|
—
|
—
|
—
|
—
|
| License And Other Revenue |
—
|
—
|
0
-93.6%
share 0.1%
|
8
+275.0%
share 4.0%
|
2
-87.5%
share 2.6%
|
16
share 83.6%
|
—
|
—
|
How these figures are calculated
Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- MIRM (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Foster City, CA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1759425
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.